Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: Relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction

Gynecological Endocrinology

Volumn 28, Issue 7, 2012, Pages 497-501

  Bayram, Fahri ^a   Kocer, Derya ^b   Ozsan, Muge ^a   Muhtaroglu, Sabahattin ^a  

^a ERCIYES UNIVERSITY   (Turkey)

^b Kayseri Training and Research Hospital ^*  (Turkey)

Author keywords

MDA; Polycystic ovary syndrome; PON1 activity; Small dense LDL C

Indexed keywords

ANDROSTENEDIONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NITRIC OXIDE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADOLESCENT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALONDIALDEHYDE; NITRIC OXIDE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; TESTOSTERONE; TURKEY; YOUNG ADULT;

EID: 84862889072     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.569607     Document Type: Article

References (33)

1. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004; 60:1-17. (Pubitemid 38183491)
2. AlexanDer CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10:83-90.
3. Yki-Järvinen H. Insulin resistance and endothelial dysfunction. Best Pract Res Clin Obstet Gynaecol 2003;17: 411-430.
4. Rizzo M, Berneis K. Low-Density lipoprotein size and cardiovascular prevention. Eur J Int Med 2006;17:77-80. (Pubitemid 43265854)
5. Dejager S, Pichard C, Giral P, Bruckert E, FeDerspield MC, Beucler I, Turpin G. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol 2001;54:455-462. (Pubitemid 34204181)
6. Moncada S, Higgs EA. The discovery of nitric oxiDe and its role in vascular biology. Br J Pharmacol 2006;147:193-201.
7. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005;43:19-29. (Pubitemid 40828829)
8. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003;80:123-127. (Pubitemid 36808867)
9. Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002;181-182:219-222. (Pubitemid 36015702)
10. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-Density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101: 1581-1590. (Pubitemid 28198486)
11. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
12. Adams J, Franks S, Polson DW, Mason HD, Abdulwahid N, Tucker M, Morris DV, Price J, Jacobs HS. Multifollicular ovaries: clinical and endocrine features and response to pulsatile nadotropin releasing hormone. Lancet 1985;2: 1375-1379.
13. Matthews DR, Hosker JP, RuDenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis moDel assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
14. FrieDewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low Density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-505.
15. Moshage H, Kok B, Huizenga JR, Jansen PL. Nitrite and nitrate Determinations in plasma: a critical evaluation. Clin Chem 1995;41:892-896.
16. Eckerson EW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: iDentification of phenotypes by their response to salts. Am J Hum Gen 1983;35: 214-227. (Pubitemid 13111118)
17. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, Dense LDL. J Lipid Res 2003;44:2193-2201. (Pubitemid 37509635)
18. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Törü ner F, Cakir N, Arslan M. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005;20: 3333-3340. (Pubitemid 41742509)
19. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod 2006;21:104-108. (Pubitemid 41794297)
20. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:4588-4593. (Pubitemid 39244474)
21. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001;34:407-413. (Pubitemid 32777851)
22. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666-4673. (Pubitemid 33020504)
23. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103:1410-1415. (Pubitemid 32220633)
24. Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H, Connell MC. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87: 742-746. (Pubitemid 34158246)
25. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol. Metab. 2003;88:576-580. (Pubitemid 36207793)
26. Nácul AP, AndraDe CD, Schwarz P, De Bittencourt PI Jr, Spritzer PM. Nitric oxiDe and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol 2007;133: 191-196. (Pubitemid 47069681)
27. Lin AL, Gonzalezn Jr R, Carey KD,Shain SA. Estradiol-17 beta affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta. Arteriosclerosis 1986;6: 495-504. (Pubitemid 16004366)
28. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol 2005;145:323-333. (Pubitemid 40896077)
29. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213-1232. (Pubitemid 35307152)
30. Nielsen F, Mikkelsen BB, Nielsen JB, AnDersen HR, Grandjean P. Plasma malondialDehyDe as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem 1997;43:1209-1214. (Pubitemid 27297265)
31. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52:879-883.
32. Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is genDer DepenDent and regulated during inflammation. Free Radic Biol Med 2003;34:824-829. (Pubitemid 36316066)
33. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Int Med 1991;151: 1925-1933.